US Patent 8,377,474: Levodopa Controlled-Release Formulation Claims, Expiration, Litigation, and Patent Landscape
US Patent No. 8,377,474 protects multiparticulate oral formulations combining immediate-release and controlled-release levodopa/carbidopa components with a physically distinct, enteric-coated carboxylic-acid component. The patent also claims specific pharmacokinetic profiles, dose ratios, particle structures, stability parameters, and methods for reducing Parkinson's disease motor fluctuations.
The patent covers the formulation architecture used in IPX066, the development formulation for Rytary, although infringement requires satisfaction of every limitation in an asserted claim. The broadest practical risk centers on claims 1, 7, and 59, which require the combined use of immediate-release and controlled-release levodopa/carbidopa components plus a separate coated carboxylic-acid component.
What drug does US Patent 8,377,474 protect?
US 8,377,474 protects controlled-release oral formulations of levodopa, principally levodopa combined with carbidopa. The patent is associated with IPX066, a multiparticulate formulation developed by Impax Laboratories and later commercialized as Rytary by Amneal Pharmaceuticals.
Patent identification
| Field |
Data |
| Patent |
US 8,377,474 B2 |
| Title |
Controlled release formulations of levodopa |
| Technology |
Oral controlled-release levodopa/carbidopa formulations |
| Original applicant |
Impax Laboratories, Inc. |
| Patent type |
Utility patent |
| Grant date |
February 19, 2013 |
| Priority framework |
U.S. and international filings relating to IPX066 controlled-release formulations |
| Principal product association |
IPX066 and Rytary |
| Active ingredient |
Levodopa |
| Decarboxylase inhibitor |
Primarily carbidopa |
| Reported expiration date |
December 28, 2027 |
| Regulatory product |
Rytary extended-release capsules, NDA 203312 |
The FDA approved Rytary on January 7, 2015. Rytary contains immediate-release and extended-release beads in a capsule and is available in multiple levodopa/carbidopa strengths.[1,2]
What are the independent claims of US 8,377,474?
The patent contains several independent claim categories:
- Formulation claims.
- Multiparticulate formulation claims.
- Stability claims.
- Method-of-treatment claims.
- Pharmacokinetic-profile claims.
Claim 1: broad formulation architecture
Claim 1 requires a controlled-release oral solid formulation containing:
- A controlled-release component with levodopa, a decarboxylase inhibitor, and one or more rate-controlling excipients.
- A separate carboxylic-acid component with a carboxylic acid and rate-controlling excipients.
- An immediate-release component with levodopa and a decarboxylase inhibitor.
- The carboxylic-acid component must be distinct and coated with an enteric polymer.
- The three components must comprise beads or granules.
The claim is compositionally broad because it does not limit the carboxylic acid to tartaric acid. It covers the listed acids in dependent claim 2 and potentially other acids falling within the claim's functional and structural boundaries.
Claim 7: multiparticulate formulation
Claim 7 repeats the core architecture with more explicit reference to levodopa and carbidopa:
- Controlled-release levodopa/carbidopa beads or granules.
- Immediate-release levodopa/carbidopa beads or granules.
- A separate enteric-coated carboxylic-acid component.
Claim 7 is commercially important because it maps closely to a capsule containing different populations of beads with different release characteristics.
Claim 59: alternative coated-component formulation
Claim 59 covers a formulation in which:
- The controlled-release levodopa/decarboxylase-inhibitor component is coated with a rate-controlling excipient.
- The carboxylic-acid component is also coated.
- The immediate-release component contains levodopa and a decarboxylase inhibitor.
- The acid is distinct and is not present in the other components.
This claim may capture manufacturing configurations that do not use identical coating or particle structures for the controlled-release and acid components.
What technical features define the patent scope?
The claims combine structural, compositional, manufacturing, and pharmacokinetic limitations. A competing product generally must be assessed across all four categories.
Core technical limitations
| Limitation |
Scope |
| Active drug |
Levodopa |
| Inhibitor |
Broadly a decarboxylase inhibitor; carbidopa is the principal claimed species |
| Release modes |
Both immediate release and controlled release |
| Acid component |
Separate carboxylic-acid component |
| Acid coating |
Enteric polymer or rate-controlling coating |
| Physical form |
Beads, granules, multiparticulates, tablets, caplets, or capsules |
| Particle separation |
Claims 44, 45, 48, and 49 require distinct or physically separated components |
| Dose ratios |
Carbidopa:levodopa approximately 1:1 to 1:10; several claims specify approximately 1:4 |
| Acid ratio |
Greater than 1:4 and less than 3:2 moles of acid to levodopa in selected claims |
| Release profile |
A first peak within about two hours and a second peak between about four and seven hours |
| Stability |
No more than 1% by weight levodopa degradation product after three months at 40°C/75% relative humidity |
| Therapeutic use |
Reduced off time, increased on time, reduced time to on, and reduced motor fluctuations |
The use of "comprising" in the principal composition claims generally leaves the claims open to additional excipients, coatings, particle populations, and formulation components, subject to ordinary claim-construction principles.
What carboxylic acids are covered by US 8,377,474?
Claim 2 lists the following acids:
- Tartaric acid
- Adipic acid
- Succinic acid
- Citric acid
- Benzoic acid
- Acetic acid
- Ascorbic acid
- Edetic acid
- Fumaric acid
- Lactic acid
- Malic acid
- Oleic acid
- Sorbic acid
- Stearic acid
- Palmitic acid
- Boric acid
The claims separately identify polycarboxylic acids and dicarboxylic acids. Tartaric acid receives special treatment in claims 28 and 56. Claims 46 and 47 combine the acid genus with the approximately 1:4 carbidopa-to-levodopa ratio and the acid-to-levodopa molar range.
The acid is not merely an excipient mixed throughout the dosage form. The strongest structural limitation requires the acid to be a distinct component, coated with an enteric polymer, and physically separated from the levodopa and decarboxylase inhibitor components.
How do the pharmacokinetic claims expand patent coverage?
Claims 13 through 18 and 73 through 76 protect performance characteristics rather than only ingredient composition.
Key pharmacokinetic limitations
| Claim group |
Required profile |
| Claims 13-14 |
Minimum concentration within six hours is at least 50% of the maximum; an early concentration is also at least 50% of maximum |
| Claim 15 |
Early concentration near 50% of maximum, maximum concentration later, and concentration at least four hours later near 50% of maximum |
| Claim 16 |
Profile substantially the same as IPX066 in Figure 1 for a 380 mg levodopa dose, or proportionally similar at another dose |
| Claim 17 |
Maximum concentration divided by concentration at any time from one to seven hours is no more than 4:1 |
| Claim 18 |
Similar median-profile requirements with a peak and later concentration at approximately 50% of peak |
| Claims 73-76 |
First peak within two hours, second peak between four and seven hours, and an intervening minimum no lower than 50% of the relevant peak |
These claims create a potential second infringement pathway. A formulation might avoid a narrow structural limitation but still raise a question under a pharmacokinetic claim if it produces the specified plasma profile. That analysis requires controlled human pharmacokinetic data, dose normalization, assay methodology, and claim construction of terms such as "substantially the same," "about," and "median."
What formulations and dosage forms are protected?
The patent is not limited to a single capsule design. Dependent claims cover multiple dosage-form configurations.
Protected dosage forms
- Multiparticulate formulations.
- Capsules containing beads or granules.
- Tablets and caplets.
- Multilayer tablets.
- Matrix tablets.
- Beads or granules pressed into tablets.
- Beads that can be removed from a capsule and sprinkled on food or liquid.
- Formulations with two controlled-release components releasing levodopa and carbidopa at different rates.
- Separate carbidopa and levodopa beads.
Claims 32 through 35 and 34 specify particle-size fractions using mesh screens. These limitations may matter in a product comparison because a generic manufacturer could attempt to use a different particle-size distribution while retaining the same active ingredients and release architecture.
What dose ratios and strengths are claimed?
The claims cover a broad carbidopa-to-levodopa ratio and several specific strengths.
Claimed ratios
- Carbidopa:levodopa from approximately 1:1 to 1:10.
- Approximately 1:4 in claims 6, 46, and 47.
- Acid-to-levodopa molar ratio greater than 1:4.
- Acid-to-levodopa molar ratio less than 3:2.
- Combined acid-to-levodopa range greater than 1:4 and less than 3:2.
Specific levodopa/carbidopa amounts
| Levodopa |
Carbidopa |
Approximate marketed relevance |
| 245 mg |
61.25 mg |
High-strength formulation |
| 195 mg |
48.75 mg |
195/48.75 mg configuration |
| 190 mg |
47.5 mg |
Specific claimed configuration |
| 180 mg |
45 mg |
Multiple acid-component examples |
| 120 mg |
30 mg |
Lower-strength configuration |
| 150 mg |
37.5 mg |
Specific claimed configuration |
Claims 50 and 51 add specific acid-component weights, each subject to a stated ±10% range. Claims 60 and 61 cover the levodopa/carbidopa quantities without the acid-component weight.
When does US Patent 8,377,474 lose exclusivity?
The reported patent expiration date is December 28, 2027. The date should be distinguished from FDA regulatory exclusivity and from the expiration of related patents listed for Rytary.
| Exclusivity category |
Relevant date or status |
| US 8,377,474 patent term |
Reported expiration: December 28, 2027 |
| Rytary NDA approval |
January 7, 2015 |
| New chemical entity exclusivity |
Not the primary protection for this product because levodopa and carbidopa were previously approved |
| Formulation patent protection |
Extends beyond approval and is separate from FDA exclusivity |
| Related Rytary patents |
May have different expiration dates and claim scope |
| Generic launch |
Subject to patent litigation, settlements, court outcomes, regulatory approval, and any applicable pediatric or other exclusivity |
The Orange Book listing of a patent does not itself establish infringement or validity. It provides notice of patents submitted by the NDA holder or patent owner and may trigger the Hatch-Waxman certification and litigation framework.[1,3]
What is the Orange Book status of the patent?
US 8,377,474 has been associated with Rytary and IPX066 formulation protection in FDA patent-listing materials. The relevant Orange Book analysis should distinguish:
- Product patents listed against Rytary.
- Patent-use codes for method-of-use claims.
- Expired, delisted, or current listings.
- Related patents covering other formulation or release features.
An Orange Book listing can support a Paragraph IV notice and a 30-month stay if the NDA holder or patent owner files timely infringement litigation under the Hatch-Waxman Act. The listing does not prevent a generic applicant from filing an ANDA or submitting a Paragraph IV certification.
Which companies are challenging Rytary and IPX066 patents?
Public challenges to Rytary patents must be analyzed on a patent-by-patent basis. A generic applicant may challenge US 8,377,474 through:
- A Paragraph IV certification.
- An ANDA litigation action under 35 U.S.C. §271(e)(2).
- Inter partes review at the Patent Trial and Appeal Board.
- Declaratory or district-court proceedings in an appropriate case.
The available patent record alone does not establish that a specific generic company has prevailed against US 8,377,474. Nor does it establish that every Rytary-related patent has the same litigation outcome. Hatch-Waxman cases often involve multiple patents, with settlements or judgments applying differently to each patent and product strength.
What Paragraph IV risks exist for a generic levodopa/carbidopa product?
A generic developer seeking approval for a Rytary-equivalent product would face several potential certification and litigation issues.
Structural infringement risk
A product is most exposed if it has:
- Immediate-release levodopa/carbidopa beads.
- Controlled-release levodopa/carbidopa beads.
- A separate enteric-coated tartaric-acid or other carboxylic-acid component.
- Similar acid-to-levodopa ratios.
- Similar particle-size ranges.
- The same or similar dose strengths.
Pharmacokinetic risk
A product could face a separate risk if its clinical profile produces:
- An early peak within two hours.
- A second peak four to seven hours after dosing.
- A trough no lower than approximately half of the peak.
- A maximum-to-maintenance concentration ratio no greater than 4:1.
Bioequivalence to Rytary may therefore create commercial and patent risk at the same time. A generic design that is sufficiently different to avoid the formulation claims may have difficulty demonstrating bioequivalence, while a bioequivalent design may resemble the claimed architecture or profile.
How strong is the patent estate for US 8,377,474?
The patent has meaningful breadth but several limitations create design-around and validity pressure.
Strengths
- The principal claims combine three distinct formulation populations.
- The acid component is separately coated and physically separated.
- Claims cover both formulation structure and pharmacokinetic performance.
- The claims include multiple acids, dose ratios, particle forms, and dosage forms.
- The claims map to a clinically differentiated extended-release profile.
Weaknesses and pressure points
- The claims require a specific multiparticulate architecture that may not cover every extended-release levodopa product.
- Functional pharmacokinetic terms may require substantial interpretation.
- Claims tied to "substantially the same" profile may raise proof and claim-construction issues.
- Some dependent claims contain overlapping or repetitive limitations.
- Prior-art analysis may focus on controlled-release levodopa, immediate-release/extended-release combinations, enteric coatings, acid-containing formulations, and multiparticulate dosage forms.
- Stability claims depend on test conditions, analytical methods, impurity definitions, and reproducibility.
The strongest commercial claims are likely those that combine the distinct acid component with the immediate-release and controlled-release levodopa/carbidopa populations. The pharmacokinetic claims can add leverage but are more fact-intensive to enforce.
What design-arounds could reduce infringement risk?
Potential design-around strategies include:
- Omitting the separate carboxylic-acid component.
- Using a single homogeneous matrix instead of distinct beads or granules.
- Incorporating the acid into the levodopa/carbidopa particles rather than physically separating it.
- Using a non-enteric release-controlling system for the acid.
- Eliminating an immediate-release levodopa/carbidopa population.
- Using a release profile outside the claimed peak and trough ranges.
- Selecting different particle-size distributions where mesh limitations are material.
- Using a different active-release architecture, such as an osmotic system, monolithic matrix, or gastroretentive system.
Each design-around must be tested against all asserted claims, including possible equivalents analysis. Avoiding the listed acid does not automatically avoid claim 1 if another carboxylic acid satisfies the claim. Conversely, eliminating the distinct acid component may address the central structural limitation across many claims.
How does US 8,377,474 compare with competing levodopa products?
| Product |
Dosage form |
Release concept |
Relationship to US 8,377,474 |
| Rytary |
Extended-release capsules |
Immediate-release and extended-release levodopa/carbidopa beads |
Closely associated with the patent |
| Sinemet |
Immediate-release tablets |
Conventional immediate release |
Generally outside the multiparticulate architecture |
| Sinemet CR |
Controlled-release tablets |
Matrix or controlled-release tablet technology |
Different dosage-form design, although other patents may apply |
| Duopa |
Enteral suspension |
Continuous intestinal infusion |
Different route and delivery system |
| Crexont |
Extended-release capsules |
Extended-release levodopa/carbidopa formulation |
Separate and potentially overlapping patent estate |
| Generic carbidopa/levodopa |
Tablets or capsules |
Varies by product |
Infringement depends on formulation and ANDA design |
The patent is more relevant to extended-release oral multiparticulate products than to conventional immediate-release tablets, enteral suspensions, or unrelated delivery systems.
What manufacturing and IP barriers remain after patent expiration?
Patent expiration will not remove all market-entry barriers. A competitor still needs:
- FDA approval through an ANDA, 505(b)(2) application, or other applicable pathway.
- Demonstration of bioequivalence or clinical efficacy, depending on the pathway.
- Acceptable dissolution and release testing.
- Control of bead coating, particle size, acid separation, and dose uniformity.
- Stability data under ICH conditions.
- Manufacturing capacity for multiparticulate encapsulation or compression.
- Clearance of related patents that expire after US 8,377,474.
- Resolution of any exclusivity, regulatory, or litigation constraints.
For a generic Rytary-like product, manufacturing reproducibility is a material barrier because the commercial value depends on maintaining both an early levodopa exposure and sustained later exposure.
Key Takeaways
- US 8,377,474 protects a three-part levodopa formulation architecture: immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and a separate enteric-coated carboxylic-acid component.
- Claims 1, 7, and 59 are the principal composition claims.
- Tartaric acid, particle structure, acid-to-levodopa ratios, dose strengths, and capsule or tablet configurations receive specific dependent-claim protection.
- Claims 13-18 and 73-76 add pharmacokinetic-profile protection.
- The reported expiration date is December 28, 2027.
- Rytary is the principal commercial product associated with the patent.
- Generic risk is highest for products using distinct immediate-release and controlled-release beads plus a separately coated acid component.
- A successful design-around would likely need to change the acid architecture, multiparticulate structure, release mechanism, or pharmacokinetic profile.
- Related Rytary patents must be reviewed separately because expiration and claim scope may differ.
FAQs About US Patent 8,377,474
Does US 8,377,474 cover all extended-release levodopa products?
No. The principal claims require a specific combination of immediate-release and controlled-release levodopa components with a distinct coated carboxylic-acid component. An extended-release product using a different architecture may fall outside the claims.
Is tartaric acid required to infringe the patent?
No. Tartaric acid is one expressly claimed option. The claims also identify multiple other carboxylic acids, and the broader claims are not limited solely to tartaric acid.
Can a generic avoid the patent by using a tablet instead of a capsule?
Not necessarily. Claims 31, 77, 80, and 81 cover tablets and caplets, including multilayer and matrix designs. The complete formulation must be compared with each asserted claim.
Does a similar pharmacokinetic profile alone establish infringement?
No. A pharmacokinetic profile may satisfy a claim directed to that profile, but infringement depends on claim construction, testing methodology, product administration, and proof that the claimed limitations are met.
Is US 8,377,474 the only patent relevant to Rytary generic entry?
No. Rytary has been associated with a broader patent and regulatory estate. A generic applicant must evaluate each Orange Book-listed patent, unlisted formulation patent, method-of-use patent, regulatory exclusivity period, and litigation or settlement restriction.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Rytary, NDA 203312. FDA Orange Book.
-
U.S. Food and Drug Administration. (2015, January 7). FDA approves new formulation of carbidopa-levodopa for Parkinson's disease. FDA.
-
U.S. Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, Chapter 1800: Patent Cooperation Treaty. USPTO.
-
United States Patent No. 8,377,474. (2013). Controlled release formulations of levodopa. U.S. Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug product labeling: Rytary (carbidopa and levodopa) extended-release capsules. FDA.
